Navigation Links
Isis Pharmaceuticals to Present at the Roth 23rd Annual OC Growth Stock Conference
Date:3/7/2011

CARLSBAD, Calif., March 7, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Roth's 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011 at 1:00 p.m. PT at the Ritz Carlton Laguna Niguel.  

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
2. Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
3. Questcor Pharmaceuticals Selects BDO USA as its Auditor
4. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
6. Endo Pharmaceuticals Launches FORTESTA™ (Testosterone) Gel for Topical Use Class III for Adult Men in the U.S. With Low Testosterone
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
9. Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
11. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... solutions, today reported financial and operational results for ... 31, 2016. 2016 Highlights ... compared to the full year 2015  ... year  Direct-to-consumer model launched in ...
(Date:3/22/2017)... today announced the appointment of Martyn Coombs as Chief ... ImaginAb, said "At ImaginAb we have exciting science and technology. Martyn ... business, particularly in commercializing and making step changes in the value ... our potential." ... Coombs is a recognized industry leader in nuclear medicine and imaging. ...
(Date:3/22/2017)... -- Ablation is the minimally invasive therapeutic tissue excision ... from cancerous or diseased tissue removal, to the ... fibrillation and others. The growing adoption of minimally ... and improvise existing ablation technologies for better patient ... is expected to grow at high single digit ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... ... California and Nevada and LABS, Inc., announced the future opening of a CLIA ... screening and serology testing used to determine the suitability of potential organ ...
(Date:3/22/2017)... ... ... Wash Tower Ltd. has released a series of six viral poo-related teaser ... standalone constant pressure bidet. , The videos in the series titled "The Adventures of ... well as on its social media pages. , Each video stars Arthur the Butler ...
(Date:3/22/2017)... ... 2017 , ... The Rett Syndrome Research Trust (RSRT) announced ... afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in a ... Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving children ...
(Date:3/22/2017)... ... 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the India ... need of skilled pediatric dentistry in Rock Hill, SC, without a referral. ... treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. , ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... entered into a research collaboration to translate advances in basic neuroscience at the ... Blythedale and beyond. The collaboration seeks to improve movement, vision, and cognition impaired by ...
Breaking Medicine News(10 mins):